Obstetrics/Gynecology
RSSArticles
-
The Progestin-Only Pill: How Effective Is It?
In this systematic literature review of 54 studies, the median typical use Pearl Index failure rate was 1.63 (range 0.00 to 14.20) and the median perfect use Pearl Index failure rate was 0.97 (range 0.40 to 6.50).
-
Is Cannabis Abuse During Pregnancy Associated with Poor Neonatal Outcomes?
Cannabis use disorder is associated with small but significant increased risks measured in multiple neonatal outcomes.
-
Postpartum Depression Medication Headed to Market
FDA approves first oral solution.
-
Pregnancy with IUDs in Place: What Is the Risk of Complications?
In this retrospective cohort study, 233 individuals who conceived with a copper intrauterine device (IUD) in place were followed. There were 44 ectopic pregnancies, 31 non-viable intrauterine pregnancies, and 158 viable intrauterine pregnancies. Of the viable pregnancies, 137 patients continued the pregnancy and, of these, 54 had the IUD removed. Those who underwent IUD removal had a lower rate of pregnancy loss (33%) compared to those who retained the IUD (61.4%).
-
Does Treatment of Gestational Diabetes Before 20 Weeks of Gestation Improve Pregnancy Outcomes?
Therapy for gestational diabetes diagnosed before 20 weeks of pregnancy was associated with a slightly decreased frequency of a composite of unfavorable neonatal outcomes compared to deferred treatment or no therapy. No significant changes were demonstrated for pregnancy-related hypertension or neonatal lean body mass between the two groups.
-
Risk-Reducing Surgery and Quality of Life for Patients with Breast and Ovarian Cancer
Risk-reducing mastectomy (RRM) and risk-reducing salpingo-oophorectomy (RRSO) for patients at high risk of breast and ovarian cancer led to decreased cancer-related distress, unaffected health-related quality of life, poorer body image after RRM, and decreased sexual function and increased menopause symptoms after RRSO.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.
-
Mothers, Babies, and HPV: Thanks for Not Sharing!
Nearly half of pregnant women in a Canadian study had vaginal swabs positive for human papillomavirus (HPV) deoxyribonucleic acid (DNA). Only about one-fourth of placentas and newborns produced by those HPV-positive women carried detectable HPV DNA, and all HPV-positive babies had cleared their positivity by 6 months of age.
-
Cabergoline: An Effective Intervention for Unwanted Lactation After Second Trimester Uterine Evacuation
In this double-blind, randomized controlled trial among 73 patients between 18 and 28 weeks’ gestation undergoing dilation and evacuation or induction of labor for abortion or fetal demise, a one-time dose of 1 mg of cabergoline compared to placebo reduced post-delivery lactation-related breast symptoms in the treatment arm (27.8% vs. 97.0%; relative risk, 0.05; 95% confidence interval, 0.01-0.33).
-
Effectiveness and Safety of Low-Dose Aspirin to Prevent Preterm Preeclampsia
An aspirin dosage of 150 mg to 162 mg per day, when started in the first trimester of pregnancy, was linked to a decreased risk of preterm preeclampsia compared to an aspirin dosage of 75 mg to 81 mg per day.